Serum cardiac troponin I concentrations decrease following treatment of primary immune‐mediated haemolytic anaemia

Cartwright, Jennifer A; Gow, Deborah J.; Gow, Adam; Handel, Ian; Reed, Nicki; Brown, Andrew; Cash, R. S. G.; Foote, A. K.; MacKenzie, David W.; Bell, R.; Mellanby, Richard J.

doi:10.1111/jsap.12379

Cited by 4 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Canine cardiac troponin I (cTn-I) and canine NT-pro-brain natriuretic peptide (Canine NT-proBNP) were used as major biomarkers for cardiac injury evaluation due to their selectivity and specificity to cardiac injury according to Cartwright et al [ 32 ] and Sawaya et al [ 33 ]. A sandwich ELISA method was adopted using Canine cTn-I/TNNI3 (canine troponin I) and Canine NT-proBNP (N-Terminal Pro-Brain Natriuretic Peptide) ELISA kit (E-EL-C0210) specific for serum samples collected from the dogs which were processed according to manufacturer's instructions and recommendations (Elabscience Biotechnology, Co., Ltd. China).…”

Section: Methodsmentioning

confidence: 99%

Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs

Danmaigoro

Selvarajah

Noor

et al. 2018

Advances in Pharmacological Sciences

View full text Add to dashboard Cite

Doxorubicin (DOX) is a potent anticancer agent with cytotoxic effects which limit its clinical usage. This effect is due to its nonselective nature causing injury to the cells as a result of reactive free oxygen radical's release. Cockleshell-derived calcium carbonate nanoparticle (CS-CaCO3NP) is a pH-responsive carrier with targeted delivery potentials. This study aimed at evaluating the toxicity effects of repeated dose administration of DOX-loaded CS-CaCO3NP in healthy dogs. Fifteen dogs with an average body weight of 15 kg were randomized equally into 5 groups. Dogs were subjected to 5 doses at every 3-week interval with (i) normal saline, (ii) DOX, 30 mg/m2, and the experimental groups: CS-CaCO3NP-DOX at (iii) high dose, 50 mg/m2, (iv) clinical dose, 30 mg/m2, and (v) low dose, 20 mg/m2. Radiographs, electrocardiography, and blood samples were collected before every treatment for haematology, serum biochemistry, and cardiac injury assessment. Heart and kidney tissues were harvested after euthanasia for histological and ultrastructural evaluation. The cumulative dose of DOX 150 mg/m2 over 15 weeks revealed significant effects on body weight, blood cells, functional enzymes, and cardiac injury biomarkers with alterations in electrocardiogram, myocardium, and renal tissue morphology. However, the dogs given CS-CaCO3NP-DOX 150 mg/m2 and below did not show any significant change in toxicity biomarker as compared to those given normal saline. The study confirmed the safety of repeated dose administration of CS-CaCO3NP-DOX (30 mg/m2) for 5 cycles in dogs. This finding offers opportunity to dogs with cancer that might require long-term administration of DOX without adverse effects.

show abstract

Section: Methodsmentioning

confidence: 99%

Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs

Danmaigoro

Selvarajah

Noor

et al. 2018

Advances in Pharmacological Sciences

View full text Add to dashboard Cite

show abstract

Myocardial injury in dogs: a retrospective analysis on etiological, echocardiographic, electrocardiographic, therapeutic, and outcome findings in 102 cases

Romito,

Palatini,

Sabetti

et al. 2024

Journal of Veterinary Cardiology

View full text Add to dashboard Cite

The use of cardiac biomarkers in dogs and cats

Blake¹

2018

Companion Animal

View full text Add to dashboard Cite

Cardiac biomarkers can be helpful in differentiating cardiac from non-cardiac disease in dyspnoeic patients; in detecting occult heart disease; and in determining prognosis in patients with both cardiac and some non-cardiac diseases. Cardiac troponin I and N-terminal proB-type natriuretic peptide are the cardiac biomarkers most widely used in clinical practice and can easily be measured from a blood sample. However, there are limitations in their use, and appropriate interpretation of results is important. This article discusses the physiology of these biomarkers and the evidence available for their use in dogs and cats.

show abstract

Serum cardiac troponin I concentrations decrease following treatment of primary immune‐mediated haemolytic anaemia

Cited by 4 publications

References 40 publications

Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs

Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs

Myocardial injury in dogs: a retrospective analysis on etiological, echocardiographic, electrocardiographic, therapeutic, and outcome findings in 102 cases

The use of cardiac biomarkers in dogs and cats

Contact Info

Product

Resources

About